Studies show that LipiGesic M provides highly effective OTC solution to migraine pain

PuraMed BioScience®, Inc., (OTCBB:PMBS), a researcher, developer, and marketer of over-the-counter (OTC) medicinal and healthcare products, announced the results of clinical trials that found its over-the-counter migraine medication product, LipiGesic^® M, has "robust efficacy".

With recent statistics showing nearly 39 million Americans suffering from migraine headaches, studies show that LipiGesic M provides a safe, highly effective OTC solution to migraine pain that performs as well as, if not better than, prescription migraine medications without the high cost, drowsiness, or the need for a doctor's visit.

The original double-blind, placebo-controlled clinical trial for LipiGesic M, completed in 2010, and published in the July 2011 issue of Headache: The Journal of Head and Face Pain, concluded that 64 percent of patients who used LipiGesic M found relief.

The results of a reanalysis of this same study published in Headache in February 2013 not only confirmed the original results, but Daniel Serrano , PhD stated, "...the efficacy of sublingual feverfew/ginger (LipiGesic M) appears robust..."

These results combined with Dr. Roger Cady 's statement describing LipiGesic M as "...an excellent first-line therapy for very early intervention..." in the article, "Advances in Drug Development for Acute Migraine," which was published in the December 2012 issue of Drugs, a medical journal evaluating drugs and drug therapies, reaffirms LipiGesic M's effectiveness.

"With at least 39 million Americans affected by migraines and LipiGesic M currently retailing for around $19.95 per box, the revenue potential for our migraine relief product is substantial," said Russ Mitchell , CEO of PuraMed BioScience. "LipiGesic M is currently available in national retail drugstore chains, such as Walgreens and CVS/pharmacy stores. Our plan to expand to additional retail chains in the United States, as well as our International distribution, should only increase our revenue potential, and thus increase value for our shareholders."

"In addition to the expanded distribution, we anticipate an increase in consumer interest," said Mitchell. "We believe that the Affordable Care Act will drive more consumers to look for cost effective ways to manage their health. Even before the Act's full implementation, many people are currently experiencing prescription limits, higher deductibles, higher co-pays, and higher employee contributions for insurance. Since the performance of LipiGesic M, is more aptly compared to prescription formulations, rather than over-the-counter products, we believe that people currently paying $40 or more for one prescription migraine treatment will turn to LipiGesic M as a highly effective, money-saving alternative that costs approximately $5 per treatment. This only increases our revenue potential."

SOURCE PuraMed BioScience, Inc.